Patent · US Active

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

US9873718B2 · kind B2 · utility

1Cited by

1References

16Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

David S. Eisenberg · Los Angeles, US
Alice Soragni · Los Angeles, US
Lin Jiang · Los Angeles, US

Key dates

Filing date	May 8, 2014
Grant date	Jan 23, 2018
Priority date	—
Expiry date	May 8, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates, e.g., to an inhibitory peptide or CPP inhibitor which specifically binds to p53 having an aberrant conformation (e.g., is aggregated or misfolded) and inhibits p53 amyloidogenic aggregation or restores proper folding of the misfolded protein. Methods of using the inhibitory peptide or CPP inhibitor (e.g. to treat subjects having tumors that comprise aggregated p53) are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.